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Abstract
Array comparative genomic hybridization (aCGH) and
microarray expression profiling were used to sub-
classify DNA and RNA alterations associated with dif-
ferential response to chemotherapy in ovarian cancer.
Two to 4 Mb interval arrays were used to map geno-
mic imbalances in 26 sporadic serous ovarian tumors.
Cytobands 1p36, 1q42-44, 6p22.1-p21.2, 7q32.1-q34
9q33.3-q34.3, 11p15.2, 13q12.2-q13.1, 13q21.31,
17q11.2, 17q24.2-q25.3, 18q12.2, and 21q21.2-q21.3
were found to be statistically associated with chemo-
therapy response, and novel regions of loss at 15q11.2-
q15.1 and 17q21.32-q21.33 were identified. Gene
expression profiles were obtained from a subset of
these tumors and identified a group of genes whose
differential expression was significantly associated
with drug resistance. Within this group, five genes
(GAPD, HMGB2, HSC70, GRP58, and HMGB1), previ-
ously shown to form a nuclear complex associated
with resistance to DNA conformation–altering chemo-
therapeutic drugs in in vitro systems, may represent a
novel class of genes associated with in vivo drug
response in ovarian cancer patients. Although RNA
expression change indicated only weak DNA copy
number dependence, these data illustrate the value of
molecular profiling at both the RNA and DNA levels to
identify small genomic regions and gene subsets that
could be associated with differential chemotherapy
response in ovarian cancer.
Neoplasia (2005) 7, 603–613
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Introduction
Ovarian cancer is the second most frequently diagnosed
gynecologic malignancy, and causes more deaths than any
other cancer of the reproductive system. The lack of reliable
methods of early detection and the absence of specific symp-
toms result in late-stage diagnosis in 70% of patients. Although
initial response rates to conventional chemotherapy among
advanced stage patients are high, resistance to chemotherapy
remains the primary factor accounting for the low 5-year sur-
vival in this patient population [1].
Ovarian cancer chemotherapy most commonly involves a
first-line combination of platinum-based compounds plus pac-
litaxel following cytoreductive surgery. Response to chemo-
therapy varies among patients, and initial treatment response
is often the most important consideration in choosing second-
line therapies. The role of CA 125 serum levels as a surrogate
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marker to assess chemotherapy response is well established
(reviewed in Ref. [2]). Both the rate of decline as well as the
absolute value of CA 125, determined after the first courses
of chemotherapy, are generally considered predictors of the
final clinical response [3].
Most investigations of drug resistance in ovarian cancer
have used anticancer drugs in vitro to select for subclones of
cell lines with resistance to the selected agent [4–9]. A
disadvantage of these approaches is that the cultured cells
used are often genomically unstable and may have acquired
in vitro genetic and epigenetic alterations that are not repre-
sentative of in vivo conditions. In addition, such models pri-
marily address acquired drug resistance, and do not provide
direct insights into the expression and genomic alterations
associated with intrinsic drug resistance.
In recent years, cytogenetic study of solid tumors has
been directed toward the identification of recurrent chromo-
somal rearrangements and patterns of copy number imbal-
ance that may pinpoint genomic regions involved in cancer
initiation, progression, drug resistance, and patients’ outcome
[10,11]. Molecular cytogenetic methods such as spectral
karyotyping and comparative genomic hybridization (CGH)
have provided useful insights concerning genomic alterations
in ovarian cancer [12,13]. However, becausemetaphaseCGH
has a resolving power of 10 to 20 Mb [14], it has not been
possible to determine genomic imbalance patterns within
cytobands. Recently, genomic and cDNA arrays (reviewed
in Ref. [15]) have provided more detailed maps of genomic
copy number alterations in tumors and, in due course, will
provide comprehensive maps of genomic imbalance in a
variety of tumors [16–18]. Moreover, high-resolution maps
of copy number imbalance are now being integrated with
expression profile data to identify clinically relevant subsets
of genes based on concomitant alterations at the DNA and
RNA levels [19–23]. Microarray expression profiling has
been utilized in a number of recent studies in ovarian cancer
(reviewed in Ref. [24]). However, no study to date has per-
formed parallel microarray expression and array compar-
ative genomic hybridization (aCGH) analyses to address
genomic imbalance and concurrent expression alterations
associated with intrinsic drug resistance in ovarian cancer.
Materials and Methods
This study was designed in three phases (Figure 1). In the
first phase, a 2- to 4-Mb genomic interval aCGH map of
genomic imbalance in 26 serous epithelial ovarian cancer
(SEOC) tumors was generated. In the second phase, sta-
tistical analysis of aCGH data sets was used to identify
cytobands in which imbalance was associated with drug
resistance. In the third phase, gene expression profiles were
obtained from a subset of tumors, patterns of gene expres-
sion associated with drug response were identified, and a
concordance analysis of the relationship between genomic
imbalance and expression levels was performed. Finally,
expression microarray prediction analysis was carried out
to identify a subset of classifier genes that could predict
chemotherapy response in ovarian cancer patients.
SEOC Tumor Samples
Snap-frozen tumor tissue samples from 26 sporadic SEOC
tumors naı¨ve to chemotherapy were selected from the Toronto
Ovarian Tissue Bank and Database. No patient included in this
study had a family history of either breast or ovarian cancer.
All samples were acquired according to the institutional guide-
lines of the Research Ethics Board. The tumor specimens
selected for this study contained at least 75% tumor content
as assessed by the surface area of histology slides cor-
responding to the snap-frozen tissues (the available clinical
data are summarized in Table 1). Patients received standard
SEOC chemotherapy (carboplatin + taxol). To be classified as
sensitive, CA 125 values from patient tumor samples had to
meet two criteria. First, the CA 125 values had to fall to below
the normal reference (f35U/ml) within three cycles of chemo-
therapy, regardless of the initial baseline. Second, the values
had to remain below the normal reference of a period of at
least 6 months from the initiation of chemotherapy. Using
these criteria within our group of samples, 16 met the criteria
for sensitivity and 10 were thus classified as resistant. Due to
the accepted variability of CA 125 values, especially in those
classified as resistant, a subset of samples was used for a
more detailed class comparison. In this group of six sensitive
and four resistant samples, the resistant tumors displayed
Figure 1. Flowchart of the experimental design.
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CA 125 levels that failed to decline below 50% of their orig-
inal postsurgical values, whereas the selected subset of sen-
sitive samples comparatively displayed the highest rate of
decline from initial baseline [3].
Tissue Arrays
A tissue array comprising 1-mm-diameter bores through
tumor-rich areas of formalin-fixed paraffin-embedded (FFPE)
tumors was designed following published methods [25] and
constructed using a standard arraying device (Beecher In-
struments, Sun Prairie, WI). Duplicate tissue cores from each
donor block were included in the tissue microarray, and sec-
tions (5 mm) were cut from the recipient tissue array block for
hematoxylin and eosin staining and interphase fluorescence
in situ hybridization (FISH) analysis.
FISH
Interphase FISH was performed on unstained 5-mm sec-
tions from the FFPE tissue array using a commercially avail-
able Spectrum Green RB1 locus probe mapping to cytoband
13q14 (Vysis, Downers Grove, IL) according to the manu-
facturer’s instructions. Slides were imaged using the Vysis
Quips SmartCapture (Vysis) imaging system. The scoring
criteria used for the interpretation of FISH results on the
FFPE sections have been previously described [19]. Chro-
mosomal gains were assigned when more than 10% of the
nuclei exhibited more than two signals.
aCGH
Genomic DNA was obtained from all tumor samples
using standard phenol chloroform extraction methods. The
normal human reference DNA was comprised of an equi-
molar mixture of DNA derived from multiple male donors
(Promega, Madison, WI). The genomic array slides were
obtained from Spectral Genomics (Houston, TX) and com-
prised 1300 large insert clones (BACs/PACs) spacedf2 to
4 Mb apart. Supplier-recommended protocol was used. In
brief, 2 mg each of genomic tumor and normal DNA was di-
rectly labeled with Cy3-dCTP or Cy5-dCTP (Amersham, Baie
D’Urfe, Canada) using random priming. Following hybridiza-
tion, the microarrays were washed using 50% formamide/2
SSC (20 minutes), 0.1% Igepal/2 SSC (20 minutes), and
0.2 SSC (10 minutes), all prewarmed to 50jC. A final wash
with deionized distilled water was carried out. Air-dried micro-
array slides were scanned with an Axon GenePix 4000A
confocal scanner, and fluorescence intensities were quanti-
fied with the GenePix Pro 3.0 software (Axon Instruments,
Union City, CA). Hybridizations were carried out in duplicate
with fluor reversals to ensure that labeling differences did
not affect imbalance assignments. Repetitive spots show-
ing >20% variation in their signal ratio were removed prior
to value averaging. Details concerning software, normaliza-
tion, and imbalance assignments have been described pre-
viously [16,18] and are available at http://www.utoronto.ca/
cancyto/. The analysis software provides data in two for-
mats: 1) the raw normalized data for each feature on the
array, and 2) the feature intensity data represented as
significant gain (two baseline standard deviations) and loss
per individual experiment. This second output was the pri-
mary analysis format used in the aCGH portion of the study.
To compensate for possible interexperimental variability,
data were normalized to show areas of significant gain or
loss in relation to each given experiment. Individual array
features were assigned a positive value for significant gain
and a negative value for significant loss based on 2 SD from
a baseline determined for each individual experiment. The
baseline threshold for each experiment is determined by the
software using the largest chromosomal region of contiguous
clones having the smallest deviation in their intensity ratios.
Spots with fluorescence intensity ratios of greater than ±2 SD
threshold are assigned as copy number imbalance and given
a score of +1 for gain and 1 for loss.
For group comparisons, the differences in log2 ratios as
well as the Fisher exact test were used to determine whether
there was any significant gain or loss of genomic content
within particular cytobands between resistant and sensitive
tumors. The Fisher exact test utilized three categories (gain,
loss, and no change), with the null hypothesis that the rela-
tive proportions of each of the three imbalance categories
would be expected to be the same in both groups. The sta-
tistical package S-Plus was used for these group compari-
sons. We reported uncorrected P values and used the
permutation-based stepdown method to correct the P values
for multiple comparisons [26].
Expression Microarrays
RNA was extracted using Trizol (Invitrogen Canada,
Burlington, Ontario, Canada). RNA quality and concentra-
tion were verified using an Agilent Bioanalyzer (Agilent
Table 1. Patient Sample Information.
Sample Number Stage Grade Surgery Age Classification
OVCA 3 IIIB 3 SOPT N/A R
OVCA 8 IIIC 2 SOPT N/A S
OVCA 33* IIIB 2 SOPT N/A S
OVCA 38 III 2 SOPT 66 R
OVCA 46* IIIB 3 N/A N/A S
OVCA 93 IIIC 3 SOPT 67 S
OVCA 123* III 3 OPT 59 R
OVCA 130* III 3 OPT 46 R
OVCA 161* IIC 3 SOPT 78 S
OVCA 162* III 3 SOPT 44 S
OVCA 180 IIC 3 OPT 88 S
OVCA 209* III 1 OPT 46 S
OVCA 237 III 3 SOPT 57 R
OVCA 239 III 3 OPT 63 S
OVCA 249* III 3 N/A 52 R
OVCA 261 IV 3 SOPT 50 R
OVCA 263 III 3 OPT 44 S
OVCA 304 III 1 SOPT 57 R
OVCA 329 III 3 SOPT 59 S
OVCA 354 III 2 SOPT 65 S
OVCA 363 III 3 SOPT 55 S
OVCA 365 III 3 SOPT 68 R
OVCA 371* III 3 N/A N/A S
OVCA 384 III 3 SOPT N/A S
OVCA 390 III 1 N/A 37 S
OVCA 498* IIIC 3 OPT 52 S
N/A: not available; NC: no change; OPT: optimally debulked; SOPT: sub-
optimally debulked.
*Extreme responders to chemotherapy.
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BioTechnologies, Palo Alto, CA). High-quality RNA was
obtained from 22 of 26 tumors. Standard optimized pro-
tocols and a full description of the cDNA arrays used in
this study can be found at the University Health Network
(UHN) Microarray Centre (http://www.microarrays.ca). Ten
micrograms of ovarian tumor total RNA or Human Univer-
sal Reference (HUR) RNA (Stratagene, La Jolla, CA) was
reverse-transcribed with Superscript II reverse transcriptase
(Invitrogen Canada) while incorporating Cy3-dCTP or Cy5-
dCTP (NEN, Boston, MA). The fluorescently labeled cDNA
were cohybridized overnight at 37jC to human 19K UHN
microarrays comprising 19,200 sequence-verified cDNA
fragments spotted in duplicate. Each of the 22 samples
was assayed with dye reversal microarray hybridizations
(to control for potential labeling differences) for a total of
44 hybridizations. Microarrays were scanned by a confocal
laser reader (ScanArray 4000; Packard BioScience, Meri-
den, CT) after stringent washes. Quantification was carried
out using GenePix Pro 3.0 (Axon Instruments). Low-quality
spots were filtered using GenePix Pro 3.0 and by visual
examination of the images. Paired dye reversal correlations
were examined by unsupervised cluster analysis. Samples
displaying correlation less than .65 were repeated (data
not shown).
Expression Microarray Data Analysis
Data warehousing, filtering, and normalization were per-
formed using the GeneTraffic software (version 2.7, Iobion;
Stratagene). Hybridizations were annotated according to
the Minimum Information About a Microarray Experiment
(MIAME) guidelines (http://www.mged.org/Workgroups/
MIAME/miame.html and Ref. [27]). The initial data set was
filtered to exclude spots flagged in the quantification pro-
cess, spots whose raw intensity was less than the local
background in either one of the two channels, spots that had
an intensity-to-background ratio of less than 2, and spots
whose raw intensity was less than 500. Locally Weighted
Scatter Plot Smoother (LOWESS) normalization by subarray
(for background, see http://www.stat.berkeley.edu/users/terry/
zarray/Html/normspie.html and GeneTraffic 2.7 Manual, Io-
bion; Stratagene) was used for normalization between the
arrays. Expression array data are available at http://www.
utoronto.ca/cancyto/OVCA2004NEO/.
Unsupervised two-dimensional hierarchical clustering
was carried out as described in Ref. [28], using Cluster 2.01
available at http://rana.lbl.gov/EisenSoftware.htm, on gene
expression values that were present in at least 80% of the
tumors (10,806 genes). Gene expression ratios were median-
centered across all samples and arrays before agglomerative
average linkage clustering using uncentered Pearson cor-
relation. All observations for a given item were weighted
equally. Clustering results were visualized using the Tree-
view software available at http://rana.lbl.gov/EisenSoftware.
htm. Significance analysis of microarrays (SAM) (Ref. [29]
and http://www-stat.stanford.edu/ftibs/PAM/) and predic-
tion analysis of microarrays (PAM) (Ref. [30] and http://
www-stat.stanford.edu/ftibs/PAM/) were performed using
the software available and published methods.
Validation by Real-Time Reverse Transcription Polymerase
Chain Reaction (RT-PCR)
Two micrograms of total RNA from six sensitive and four
resistant ovarian tumors classified as extreme responders
according to the patients’ CA 125 profiles was reverse-
transcribed in a 100-ml reaction mixture comprising 5.5 mM
MgC12, 500 mM of each dNTP, 2.5 mM random hexamers,
0.4 U/ml RNase inhibitor, and 3.125 U/ml MultiScribe Reverse
Transcriptase (Applied Biosystems, Foster City, CA) under
the following conditions: 25jC for 10 minutes, 48jC for
30 minutes, and 95jC for 5 minutes. Real-time relative
quantitative PCR was performed in triplicate using the ABI
PRISM 7900HT Sequence Detection system (Applied Bio-
systems) according to the manufacturer’s instructions. A
subset of genes was chosen for validation using commer-
cially available Assays-on-Demand probe primer sets with
provided master mix (Applied Biosystems). The following
PCR conditions were used: 50jC for 2 minutes, 95jC for
10 minutes, followed by 40 cycles of 95jC for 15 seconds
and 60jC for 1 minute. Human cyclophilin A was used as an
endogenous control because it resulted in minimum varia-
tion throughout the samples and has been previously used
to validate cancer microarray expression data by real-time
RT-PCR [31]. The initial copy numbers of RNA targets can
be quantified using real-time PCR analysis based on thresh-
old cycle (Ct) determinations. Ct is defined as the cycle at
which a statistically significant increase in fluorescence
(above background signal contributed by the fluorescence-
labeled oligonucleotides within the PCR reaction) is de-
tected. The threshold cycle is inversely proportional to the
log of the initial copy number. The Ct value of human cyclo-
philin A was subtracted from each Ct value of OVCA or HUR
sample for normalization and the ratio of OVCA tumor:HUR
RNA expression was calculated so that real-time RT-PCR
and microarray data could be compared.
Results
In this study, aCGH analysis improved the resolution of
such regions including 9q21.11-q33.1 and 11p15.1-pter, as
well as identified novel regions of loss at 15q11.2-q15.1 and
17q21.32-q21.33 that have not been reported in ovarian
cancer. When imbalance profiles of resistant tumors were
compared to sensitive tumors, 13 regions of the genome
were strongly associated with differentiating responses. Par-
allel expression analysis by cDNA microarrays revealed a
nuclear complex comprised of GAPD, HMGB2, HSC70,
GRP58, and HMGB1 whose RNA levels were lower in the
resistant tumors in comparison to the sensitive group.
Overall aCGH Analysis of 26 SEOC Tumors
The patterns of genomic imbalances of DNA overrepre-
sentation and underrepresentation at 2- to 4-Mb intervals in
26 SEOC tumors were identified by aCGH (Figure 2). All
imbalance data from individual aCGH profiles of each tumor
are published as supporting information at http://www.
utoronto.ca/cancyto/OVCA2004NEO/. Losses at 1p, 4q,
6q, 8p, 9q, 13q, 16q, 17p, and 18q were present. Gains at
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1q, 3q, 8q, 12p, and 20q were also detected, but no focal
high copy number gene amplification was evident within
this study group. To validate the imbalances detected at
13q14 by aCGH, interphase FISH analysis was performed
using a 13q14-specific probe (RB1 gene) (data not shown).
In 17 of 23 samples studied by interphase FISH, imbalances
were in agreement with aCGH. For three samples, alter-
ations in ploidy levels or cellular heterogeneity within tissue
sections were identified. The remaining three samples could
not be scored as a result of poor signal intensity.
DNA Copy Number Changes Associated with Differential
Treatment Response
The samples were divided into sensitive and resistant
groups, as described earlier, for a more detailed analysis of
the patterns of genomic imbalances associated with differ-
ential responses to chemotherapy (Figure 3). Based on the
number of BAC clones subject to imbalance, in comparison
to the total number of clones analyzed, a group analysis of
the overall percentage of the genome altered indicated that
the resistant group had an increased level of genomic
imbalance (8.3% gain, 2.4% loss) compared to the sensitive
group (4.4% gain, 1.1% loss) (data not shown). Moreover,
consistent with this elevated percentage of genomic change,
twice as many imbalances were identified in the resistant
group (55 losses/gains) compared to the sensitive group
(28 losses/gains). The Fisher exact test was used to com-
pare the resistant and sensitive groups in three categories
(gain, loss, and no change) to determine which contiguous
genomic regions were statistically concordant with differen-
tial treatment response (Table 2, Figure 3). Three particular
regions of imbalance are identified as 13q12.2-13q13,
1p36.33, and 17q11.2.
Microarray Expression Profiling
Unsupervised two-dimensional hierarchical clustering
(Figure W1) was performed using expression data derived
from 22 of 26 SEOC tumor cohorts classified as sensitive
or resistant based on their CA 125 patterns. The clustering
pattern observed did not clearly separate tumors based on
response to chemotherapy and, consistent with these find-
ings, supervised analysis using SAM only identified a limited
number of genes differentially expressed in this group com-
parison (data not shown). A subset of 10 tumor samples was
then selected from patients exhibiting the most extreme differ-
ences in CA 125 response. Unsupervised two-dimensional
hierarchical clustering (Figure 4) clearly stratified this subset
into a resistant and a sensitive group. A cluster of 1301 genes
(highlighted in yellow) largely overlapped with those of a
similar-sized gene cluster apparent in the hierarchical cluster-
ing performed on the complete sample cohort (highlighted in
yellow in Figure W1).
Figure 2. Summary of all aCGH findings using 26 SEOC samples. Overall gains and losses as determined by mean values for individual features are shown to the
right of each chromosome ideogram as green and red bars, respectively. In this analysis, closely linked BACs that consistently exhibited fluorescence intensities
that deviated by 2 SD or more were used to generate the average imbalance profile (traced in red).
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Identification of Differentially Expressed Genes Associated
with Treatment Response
The large discriminating gene cluster identified in Figure 4
contains a majority of the statistically significant expres-
sion changers identified by SAM analysis, and this large
cluster contains child nodes with a preponderance of genes
involved in: 1) nucleus/DNA binding; 2) nucleus/metal ion
binding; 3) cell cycle/cyclin–dependent protein kinase; 4)
Table 2. Fisher Exact Test: Differential Cytoband Regions Between Resistant and Sensitive Groups.
Cytoband Mb Size (Mb Range) P Range* Gene of Interest within
Cytoband (Cytoband)y
Relative Copy
Nb Change (R/S)z
Copy Nb-Resistant
Versus Normal§
Copy Nb-Sensitive
Versus Normal§
1p36.33 0.515 (1.164–1.679) 0.049–0.056 TP73 (1p36.3) U  NC
1p36.13 1.448 (19.705–18.257) 0.0009–0.04 U  NC
1q42-44 20.518 (222.771–243.289) 0.001–0.06 LGALS8 (1q43) O + NC
6p22.1-p21.2 11.491(28.342–39.833) 0.019–0.09 BAK1 (6p21.31) U NC +
7q32.1-q34 11.873 (126.656–138.529) 0.012–0.029 BRAF (7q34) U NC +
9q33.3-q34.3 13.285 (122.613–135.898) 0.006–0.09 O NC 
11p15.2 1.559 (14.206–15.765) 0.043–0.043 RRAS2 (11p15.2) O NC 
13q12.2-q13.1 5.22 (25.719–30.939) 0.004–0.0062 BRCA2 (13q12.3) O NC 
13q21.31 0.385 (61.538–61.923) 0.025–0.046 O NC 
17q11.2 1.421 (30.848–32.269) 0.017–0.059 NF1 (17q11.2) O NC 
17q24.2-q25.3 13.974 (64.589–78.563) 0.021–0.15 BIRC5 (17q25.3) O NC 
18q12.2 1.143 (31.407–32.550) 0.011–0.043 U  NC
21q21.2-q21.3 3.982 (23.885–27.867) 0.0085–0.080 U  NC
(+) Gain in copy number when compared to normal; () loss in copy number when compared to normal.
*Uncorrected P values from the Fisher exact test for the features representing the region.
yBAK1: BCL2-like 7 protein cell death inhibitor 1 apoptosis regulator BAK Bcl-2 homologous antagonist/killer; BIRC5: baculoviral IAP repeat-containing protein 5,
survivin; BRAF: v-raf murine sarcoma viral oncogene homolog B1; BRCA2: breast cancer 2, early onset; LGALS8: lectin, galactoside-binding, soluble, 8 (galectin 8);
NF1: neurofibromin 1 (neurofibromatosis, von Recklinghausen disease, and Watson disease); RRAS2: related RAS viral (r-ras) oncogene homolog 2; TP73: tumor
protein p73.
zU: underrepresented copies in resistant compared to the sensitive group; O: overrepresented copies in the resistant compared to the sensitive group.
§NC: no change in copy number when compared to normal.
Figure 3. Whole genome plot of the relative difference in normalized log2 average ratios between the 10 resistant and 16 sensitive samples. Positive (above
baseline) and negative (below baseline) deflections of the profile indicate the mean overrepresentation and underrepresentation of the region in resistant versus
sensitive samples, respectively. The vertical pale gray bars correspond to the contiguous array features differentially identified using the Fisher exact test (see
Table 2), with bars above the profile indicating overrepresentation and bars below indicating underrepresentation. Horizontal dark gray bars above (gain) and below
(loss) the profile highlight the features with fluorescence intensity ratios greater than threshold.
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microtubule/cytoskeleton; and 5) nucleus/actin cytoskel-
eton engineering.
Class comparison by statistical supervised analysis using
SAM identified 173 clones (corresponding to 123 unique iden-
tified genes), which were statistically differentially expressed
between the two classes with a fold change (FC) difference
of at least 2 and a false discovery rate (FDR) <1%. The com-
plete list of differentially expressed genes identified is avail-
able in supplementary materials (Table W1).
Microarray Prediction Analysis
We employed the ‘‘nearest shrunken centroid’’ method-
ology [30] that employs leave-one-out cross validation
(LOOCV) to identify the most relevant classifier genes ca-
pable of predicting chemotherapy resistance in SEOC pa-
tients. When applied to the present expression data set from
the 10 extreme cases, the PAM algorithm identified a set of
22 genes and ESTs that could predict with 100% accuracy
the class of the test sample during LOOCV on this patient
Figure 4. Analysis of the 10 extreme responders using unsupervised hierarchical clustering. (A) The relative expression patterns of genes that are color-coded in
red (up), green (down), black (no change), or grey (data missing) clearly stratifies the sensitive (S; pink) and resistant (R; blue) samples into two major nodes. A
major gene cluster that includes most genes identified by SAM analysis is highlighted with a vertical yellow bar. (B) A magnified view of subclusters that include
large numbers of genes belonging to functional categories of 1) nucleus/DNA binding; 2) nucleus/metal ion binding; 3) cell cycle/cyclin –dependent protein kinase;
4) microtubule/cytoskeleton; or 5) nucleus/actin cytoskeleton engineering. (C) Relative position and expression patterns of genes identified by PAM analysis.
Genes identified by PAM analysis are indicated by an asterisk (*). Genes identified only by SAM analysis are indicated by two asterisks (**).
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sample set. The complete list of these clones is presented
in Table 3.
Data Mining
The possible functional roles of 15 of 22 clones were
examined. Seven clones could not be further analyzed be-
cause ambiguity in their DNA sequence prevented their proper
annotation. By applying a data mining software (Pathway-
Assist, Iobion Informatics; Stratagene) to the list of 22 clones
identified by PAM, a nuclear complex comprised of two pre-
dictive genes identified by PAM (GAPD and HMGB2) and
three additional genes identified by SAM (HSC70, GRP58,
and HMGB1) was revealed. This nuclear complex was pre-
viously reported as being involved in resistance to DNA
conformation–altering chemotherapeutic drugs [32].
To validate the expression findings derived from micro-
array analysis, the levels of expression of GAPD, HMGB2,
HSC70, GRP58, and HMGB1 were measured by real-time
RT-PCR. The results obtained are shown in Figure W2 and
both real-time RT-PCR and microarray data agree in the
direction of expression (i.e., up or down). All five genes dis-
played lower expression levels in resistant samples than in
sensitive samples.
Correlation between Overall Pattern Gene Expression
and DNA Copy Number
The level of agreement between expression and copy
number changes was tested with the simple j coefficient
(Table W2). Overall comparison between expression level
and aCGH copy numbers, including the no changers, showed
91% agreement. If expressed genes identified as differen-
tial in the two groups were solely considered, 8.2% of the
genes agreed with copy number differences. When cor-
rected for chance agreement for the twomethods by Cohen’s
j, a slight agreement between the two data sets (j^ =
0.0230; 0 < j^ < 1) was indicated but was not statistically
significant (j^* = 0.1316; j^* < 1.96).
Discussion
In keeping with classic cytogenetic studies and metaphase-
based CGH findings, the imbalance profiles identified in this
study are complex and characterized by low-level gains and
losses that affect all chromosomes except chromosome 10.
The consensus pattern of imbalance was, in general, con-
sistent with findings previously reported in ovarian cancer by
metaphase CGH (reviewed in Ref. [33] and available from
CGH databases: http://www.ncbi.nlm.nih.gov/; http://www.
progenetix.net; http://amba.charite.de/fksch/cghdatabase/
index.htm; and http://www.helsinki.fi/cmg/cgh_data.htm).
aCGH permitted identification of cytoband imbalances
(Table W3) within the larger genomic intervals identified in
published metaphase CGH studies [34,35] and allelic imbal-
ance findings [36,37]. For example, losses at distal 1p have
been consistently reported, but aCGH localizes the minimal
region of consistent loss to 1p36.11-pter in 18/26 tumors.
Similarly, the recurrent gain at 6p was localized to two inter-
vals at 6p21.1-p21.31 and 6p22.1-pter. Moreover, aCGH
identified small focal genomic imbalances not previously de-
tected by metaphase CGH, such as losses at 15q11.2-q15.1
Table 3. List of Genes Identified by PAM Analysis That Discriminate between Resistant and Sensitive Groups.
Clone ID or
Accession Number*
Fold Changey Name Symbol Cytoband
Upz
BM976649 2.01892 Sphingosine-1-phosphate lyase 1 SGPL1 10q21
Down§
162892 10.39 Highly similar to Ig lambda chain C regions N/A N/A
182721 6.24 Immunoglobulin lambda joining 3 IGLJ3 22q11.1-q11.2
135961 4.99 Solute carrier family 25 SLC25A5 Xq24-q26
5922013 4.84 Tubulin, beta polypeptide TUBB 6p25
300017 4.18 Apolipoprotein B APOB 2p24-p23
4876644 4.08 Tubulin, beta 5 TUBB5 19p13.3
261822 3.79 Homo sapiens, clone IMAGE: 5728597 N/A 22q11.23
AL536766 3.72 Tubulin, beta polypeptide paralog MGC8685 6p25
5806720 3.31 Glyceraldehyde-3-phosphate dehydrogenase GAPD 12p13
5740157 3.26 Tyrosine 3-monooxygenase/tryptophan
5-monooxygenase activation protein
YWHAQ 2p25.2-p25.1
5556148 3.23 Small nuclear ribonucleoprotein polypeptides B and B1 SNRPB 20p13
504180 2.75 H. sapiens, clone IMAGE: 5742072, mRNA N/A N/A
267145 2.74 High-mobility group box 2 HMGB2 4q31
471144 2.64 Electron transfer flavoprotein, beta polypeptide ETFB 19q13.3
270849 2.48 H. sapiens– transcribed sequences N/A N/A
AL558551 2.48 Glutathione peroxidase 4 (phospholipid hydroperoxidase) GPX4 19p13.3
5932330 2.2 SH3 domain binding glutamic acid-rich protein like 3 SH3BGRL3 1p35-p34.3
N/A: not available.
*Four of 22 PAM clones are not listed above because they were redundant or not sequence-verified.
yRelative fold change between the two classes (resistant/sensitive).
zList of genes whose transcript levels are greater in the resistant group compared to the sensitive group.
§List of genes whose transcript levels are lower in the resistant group compared to the sensitive group.
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and 17q21.32-q21.33. Imbalances such as gains at 1q11-
q25.3, 3q22.3-qter, 8q11-qter, and 20q12-qter have been
previously detected in a wide variety of epithelial tumors [33]
including ovarian cancer, but improved resolution has been
obtained in other areas including losses at 9q21.11-q33.1
and 11p15.1-pter.
Resistant tumors were found to have twice as much
genomic imbalance as sensitive tumors. These data suggest
that the resistant group of SEOC tumors would have a
greater capacity to adapt to the selective pressures of
chemotherapy by virtue of their elevated frequency of ge-
nomic rearrangement in comparison to the sensitive group.
The interval 13q12.2-13q13.1, which comprisesf400 kb
of DNA, contains the BRCA2 gene (13q12.3), a tumor-
suppressor gene known to be mutated in a high percentage
of hereditary ovarian cancers [38]. This region was subject to
loss in 72% of the 16 sensitive tumors. It is possible that
acquired loss of BRCA2 and cognate cellular repair functions
could enhance susceptibility to chemotherapy. In this con-
text, Kudoh et al. [34] investigated ovarian tumors resistant
or sensitive to chemotherapy using metaphase CGH, and
found that the region 13q12-14 was more often gained in the
resistant ovarian cancer in comparison to sensitive tumors.
The f500-kb region, 1p36.33, was found to be under-
represented in resistant tumors relative to sensitive tumors
(Table 2). This small region of chromosome 1 contains the
TP73 gene, and it has recently been reported that dereg-
ulation and overexpression of specific p73 isoforms are asso-
ciated with reduced overall survival in ovarian cancer [39]. By
analogy with p53, it is plausible that genomic imbalance (loss
or gain) of 1p36.33 may alter the spectrum of TP73 isoforms
and influence treatment response. Similarly, the NF1 gene
situated in 17q11.2 has also been studied previously in ovar-
ian cancer cell lines [40]. The authors of this study reported
that overexpression and imbalance of type II and type I iso-
forms of NF1 were associated with differentiation arrest and,
potentially, treatment response. The observation of over-
representation of 17q11.2 in resistant tumors may implicate
a role for NF1 in chemotherapy resistance.
Unsupervised two-dimensional hierarchical clustering
(Figure 4) analyses of expression microarray data using a
subset of 10 tumor samples exhibiting the most extreme
differences in CA 125 response revealed a large cluster of
1301 genes (highlighted in yellow) that was particularly
important in the segregation of these two groups. Interest-
ingly, the genes in this cluster largely overlap with those of a
similar-sized gene cluster apparent in the hierarchical clus-
tering performed on the complete sample cohort (highlighted
in yellow in Figure W1). However, it is likely that, due to the
relative heterogeneity of the 22 samples, the influence of this
clusterwas insufficient in completely stratifying the two groups.
Class comparison by SAM identified 173 clones, which in-
cluded 123 unique identified genes (Table W1). Importantly,
there was a significant difference (P < .05) in the proportion
of genes involved in DNA binding, regulation of transcrip-
tion, cell cycle and growth, and metal ion binding between
the 173 differentially expressed genes and the gene popula-
tion on the H19K microarray (data not shown). An in-depth
analysis of the 123 genes differentially expressed between
sensitive samples and resistant samples is beyond the
scope of this study. We have focused instead on the subset
of these genes that can predict chemotherapy response as
described below.
We employed the ‘‘nearest shrunken centroid’’ method-
ology [30] to identify the most relevant classifier genes
capable of predicting chemotherapy resistance in SEOC
patients. This approach was used by Tibshirani et al. [30]
on microarray data obtained by Khan et al. [41] on blue cell
tumors of childhood and by Golub et al. [42] on leukemia.
Tibshirani et al. demonstrated that this method was supe-
rior to both a neural network method and to the approach
taken by Golub et al. [42]. The complete methodology of
PAM is described in details in Ref. [30] and uses a LOOCV, a
strategy particularly useful when identifying classifiers genes
in smaller sample sizes [43]. When applied to the present
expression data set from the 10 extreme cases, the PAM
algorithm identified a set of 22 genes and ESTs that could
predict with 100% accuracy the class of the test sample
during LOOCV. The complete list of these clones is pre-
sented in Table 3.
Of the 22 clones identified by PAM analysis, possible
functional roles for 15 of the clones were examined (seven
had ambiguous DNA sequence, which prevented their
proper annotation). b-Tubulin subtypes accounted for 3 of
15 discriminating identified genes differentially expressed
between the sensitive and resistance groups. This is of
interest because taxanes are thought to function by stabiliz-
ing microtubules—a process that eventually leads to apop-
tosis. Previous studies have indicated that resistance to
taxanes may be a consequence of altering the relative
amount of the various subtypes of b-tubulin, thereby decreas-
ing the efficiency of microtubule stabilization by taxol (re-
viewed in Ref. [44]). In these studies, altered levels of the
different b-tubulin isotypes were observed as a conse-
quence of acquiring resistance to chemotherapy. Because
the SEOC tumors in the present study were naı¨ve to chemo-
therapy, the results presented here suggest that, before
chemotherapy, some patients may already express varying
levels of b-tubulin isotypes, which could result in differential
response to taxol.
With PathwayAssist, a software that identifies links be-
tween the user’s genes of interest based on mining Pub-
Med’s abstracts and public biologic databases, a nuclear
complex comprised of two predictive genes identified by
PAM (GAPD and HMGB2) and three additional genes
(HSC70, GRP58, and HMGB1) was revealed. This nuclear
complex was previously reported as being involved in re-
sistance to DNA conformation–altering chemotherapeutic
drugs [32]. In contrast, Sugimura et al. [45] reported in-
creased in vitro expression of HSC70 in a human ovarian
adenocarcinoma cell line rendered resistant to paclitaxel.
Concordant with our results, Vargas-Roig et al. [46] reported
decreased HSC70 levels in breast cancer patient tumors
resistant to DNA-targeting drugs. In addition, it was shown
that the potency of platinum-related drugs could be in-
creased by inducing HMGB1 transcription [47].
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Although HSC70, GRP58, and HMGB1 were not identi-
fied by PAM as predictive of drug resistance, HSC70 was
identified by SAM as significantly differentially expressed
between resistant and sensitive samples (Table W1).
GRP58 and HMGB1 were also found to be differentially ex-
pressed between the two groups, but with FCs of 1.7 and 1.3,
respectively, and with a slightly higher FDR (5–10%). The
present finding, that all five genes are significantly down-
regulated in patients resistant to chemotherapy, strongly
suggests their involvement in ovarian cancer resistance to
cisplatin-related drugs. Although overall comparison be-
tween expression level and aCGH copy numbers, including
the no changers, showed 91% agreement, when expressed
genes identified as differential in the two groups were solely
considered, 8.2% of the genes agreed with copy number
differences. This level of agreement was not statistically
significant (n^* = 0.1316; j^* < 1.96) by Cohen’s j method.
Because the general distribution of the clones on the H19K
arrays was not significantly different from the distribution of
genes in the genome (based on Build 34b, version 2), lack of
concordance cannot be due to poor representation of the
genome in the H19K clone set. Previous studies that exam-
ined concordance between expression changes and geno-
mic imbalance have been conflicting [23,48,49], eluding to
varying degrees of epigenetic regulation in different can-
cers. The class comparison presented in this report was
applied to a homogeneous group of advanced stage SEOC
tissues that were prospectively identified as resistant or sen-
sitive to chemotherapy. Although a subset within this study
group identified a set of genes predictive for extreme non-
responsiveness, this same subset did not provide any fur-
ther information at the DNA level. It is possible that partial
chemotherapy response may be determined based on copy
number differences at the DNA level. However, extreme
nonresponsiveness may be mediated by different processes
more dependent on RNA expression.
In conclusion, these data illustrate the value of molecular
profiling at both the RNA and DNA levels to identify small
genomic regions, and gene subsets that could be associated
with differential chemotherapy response in ovarian cancer.
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Figure W2. Validation by real-time RT-PCR of members of the nuclear
complex. Arithmetic means representing relative expressions of each gene in
the resistant and sensitive groups are depicted with hashed (m) and solid (n)
bars, respectively. Expression levels were calibrated against Human Uni-
versal Reference. The error bars represent standard deviation.
Figure W1. Analysis of 22 samples using unsupervised hierarchical clus-
tering. Sensitive (S; pink) and resistant (R; blue) samples are interspersed
throughout the dendogram. Relative expression levels of genes are depicted
in green (down), red (up), black (no change), or grey (data missing). The yel-
low vertical bar highlights a major gene cluster within which most genes
identified as differentially expressed between the sensitive and resistant
groups by SAM analysis were localized.
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Table W1. Genes Identified by SAM* Analysis that are Differentially Expressed between the Resistant and Sensitive Groups.
Clone ID Fold Changey Name Gene Symbol Cytoband
UPz
296275 15.43 H19, imprinted maternally expressed untranslated mRNA LOC283120 11p15.5
109357 4.73 placenta-specific 4 PLAC4 21q22.3
53087 3.65 hypothetical protein LOC283922 LOC283922 16q22.3
158123 3.32 ATPase, H+ transporting, lysosomal 56/58kDa ATP6V1B1 2p13.3
470393 3.29 matrix metalloproteinase 7 MMP7 11q22.2
5301677 2.85 retinol binding protein 1, cellular RBP1 3q23
148914 2.76 Homo sapiens mRNA; cDNA DKFZp564B076 N/A 6p21.1
29988 2.42 pre-B-cell leukemia transcription factor 1 PBX1 2q23.1
149421 2.09 dual specificity phosphatase 1 DUSP1 5q35.1
2262605 2.07 Homo sapiens EMX2OS mRNA, complete sequence N/A 10q26.11
501985 2.02 sphingosine-1-phosphate lyase 1 SGPL1 10q22.1
DOWN§
162892 10.39 Homo sapiens cDNA FLJ26905 fis N/A 22q11.22
146669 6.73 immunoglobulin lambda joining 3 IGLJ3 22q11.22
308924 6.47 hemoglobin, epsilon 1 HBE1 11p15.4
293298 5.62 Homo sapiens IGL mRNA for immunoglobulin lambda light chain N/A 22q11.22
4701351 4.94 ferritin, light polypeptide FTL 19q13.33
5922013 4.84 tubulin, beta polypeptide TUBB 6p25.2
33203 4.77 tubulin, alpha 3 TUBA3 12q13.12
5784795 4.57 metallothionein 2A MT2A 16q12.2
163221 4.56 Homo sapiens clone P2-114 anti-oxidized LDL
immunoglobulin light chain
N/A 22q11.22
110243 4.47 Homo sapiens cDNA FLJ26905 fis, clone RCT01427, highly similar to N/A 22q11.22
300017 4.18 apolipoprotein B APOB 2p24.1
5923231 4.10 RAN, member RAS oncogene family RAN 12q24.33
4876644 4.08 tubulin, beta, 5 TUBB5 19p13.3
261822 3.79 Homo sapiens, clone IMAGE:5728597 N/A 22q11.23
503601 3.74 glyceraldehyde-3-phosphate dehydrogenase WT1 11p13
184151 3.72 tubulin, beta, 4 TUBB4 16q24.3
33204 3.72 tubulin, beta polypeptide paralog MGC8685 6p25.2
303100 3.68 fibronectin 1 FN1 2q35
5762339 3.65 membrane targeting (tandem) C2 domain containing 1 MTAC2D1 14q32.12
198960 3.42 hemoglobin, gamma G HBG2 11p15.4
470628 3.39 Homo sapiens cDNA clone IMAGE:5288757 N/A 1p32.2
5926230 3.36 peroxiredoxin 1 PRDX1 1p34.1
229610 3.35 Homo sapiens transcribed sequence N/A 11p15.4
5749861 3.34 immunoglobulin lambda locus IGL@ 22q11.22
5422775 3.32 ribosomal protein S5 RPS5 19q13.43
208059 3.27 heat shock 70kDa protein 8 HSC70 11q24.1
5740157 3.26 tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation pro YWHAQ 2p25.1
5421424 3.19 enolase 1 ENO1 1p36.23
5454961 2.88 Homo sapiens transcribed sequence N/A 15q25.1
120559 2.87 metallothionein 1F MT1F 16q12.2
5406583 2.82 H2A histone family, member Z H2AFZ 4q23
5806641 2.81 histone H2A.F/Z variant H2AV 15q26.1
212856 2.79 hemoglobin, zeta HBZ 16p13.3
5925346 2.77 chromosome 7 open reading frame 17 LOC51142 7p11.2
504180 2.75 Homo sapiens, clone IMAGE:5742072 N/A 6p22.3
267145 2.74 high-mobility group box 2 HMGB2 4q34.1
154975 2.69 Homo sapiens transcribed sequence N/A 22q11.22
471144 2.64 electron-transfer-flavoprotein, beta polypeptide ETFB 19q13.41
307027 2.59 heterogeneous nuclear ribonucleoprotein A2/B1 HNRPA2B1 7p15.2
27920 2.57 mitogen-activated protein kinase kinase kinase 7 interacting protein 1 MAP3K7IP1 22q13.1
297215 2.55 annexin A5 ANXA5 4q27
145972 2.54 KIAA0101 gene product KIAA0101 15q22.31
5111837 2.52 cofilin 1 CFL1 11q13.1
5934101 2.50 pyruvate kinase, muscle PKM2 15q23
4734377 2.49 ubiquitin B UBB 17p11.2
270551 2.48 CD44 antigen CD44 11p13
155222 2.48 glutathione peroxidase 4 GPX4 19p13.3
3546201 2.45 ribosomal protein L10 RPL10 Xq28
5494320 2.45 heat shock 90kDa protein 1, alpha HSPCA 14q32.32
488225 2.44 ribosomal protein S19 RPS19 19q13.2
139590 2.43 RAN binding protein 1 RANBP1 22q11.21
29774 2.43 eukaryotic translation initiation factor 2 EIF2S2 2q31.1
341798 2.34 ubiquinol-cytochrome c reductase hinge protein UQCRH 1p36.13
5809010 2.31 putative translation initiation factor SUI1 17q21.2
5533075 2.30 small nuclear ribonucleoprotein polypeptides B and B1 SNRPB 20p13
490368 2.29 ribosomal protein S16 RPS16 19q13.2
489898 2.27 nuclease sensitive element binding protein 1 NSEP1 1p34.2
300041 2.26 non-metastatic cells 1 NME1 17q21.33
(continued on next page)
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Table W1. (continued ).
Clone ID Fold Changey Name Gene Symbol Cytoband
343295 2.25 lectin, galactoside-binding, soluble, 1 (galectin 1) LGALS1 22q13.1
138280 2.23 DKFZp564J157 protein DKFZP564J157 12q13.13
3916469 2.23 NHP2 non-histone chromosome protein 2-like 1 NHP2L1 22q13.2
5540049 2.22 Homo sapiens transcribed sequence HCP15 7p15.3
5475005 2.22 Homo sapiens similar to ribosomal protein L18a RPL18A 19p13.11
4126974 2.22 malate dehydrogenase 2, NAD MDH2 7q11.23
230534 2.22 hemoglobin, alpha 2 HBA1 16p13.3
5785893 2.21 ATP synthase, H+ transporting, mitochondrial F0 complex, subunit c ATP5G3 2q31.1
5431259 2.21 glyceraldehyde-3-phosphate dehydrogenase GAPD 12p13.31
278772 2.21 stearoyl-CoA desaturase SCD 10q24.31
5770525 2.21 activating transcription factor 4 ATF4 22q13.1
5932330 2.20 SH3 domain binding glutamic acid-rich protein like 3 SH3BGRL3 1p36.11
5704441 2.20 DEAD (Asp-Glu-Ala-Asp) box polypeptide 5 DDX5 17q24.1
5528790 2.19 excision repair cross-complementing rodent repair deficiency, comp ERCC1 19q13.32
4762963 2.19 ribosomal protein S13 RPS13 11p15.1
505381 2.19 syndecan 2 SDC2 8q22.1
4702445 2.19 ferritin, heavy polypeptide 1 FTH1 11q12.3
5806598 2.18 keratin 8 KRT8 12q13.13
5927927 2.17 ribosomal protein L10a RPL10A 6p21.31
200573 2.16 CDC28 protein kinase regulatory subunit 1B CKS1B 1q22
346784 2.15 alpha-2-HS-glycoprotein AHSG 3q27.3
209207 2.15 superoxide dismutase 1 SOD1 21q22.11
295004 2.14 hepatoma-derived growth factor HDGF 1q23.1
137317 2.13 chromosome 6 open reading frame 49 C6orf49 6p21.1
186682 2.13 trefoil factor 1 TFF1 21q22.3
5788140 2.13 ras homolog gene family, member A ARHA 3p21.31
5420166 2.12 actin, alpha 2, smooth muscle, aorta ACTA2 10q23.31
4772211 2.12 calmodulin 2 CALM2 2p21
4347418 2.10 high-mobility group nucleosome binding domain 1 HMGN1 21q22.2
5455241 2.09 solute carrier family 25 SLC25A5 Xq24
471551 2.09 Homo sapiens transcribed sequence N/A 8q13.2
505115 2.09 chaperonin containing TCP1, subunit 8 (theta) CCT8 21q21.3
5927445 2.08 peroxiredoxin 6 PRDX6 1q25.1
200190 2.07 nascent-polypeptide-associated complex alpha polypeptide CA 12q13.3
151473 2.06 G1 to S phase transition 1 GSPT1 16p13.13
221318 2.05 CDC28 protein kinase regulatory subunit 2 CKS2 9q22.2
5926362 2.04 solute carrier family 25 (mitochondrial carrier; phosphate carrier SLC25A3 12q23.1
4304010 2.04 stathmin 1/oncoprotein 18 STMN1 1p36.11
5270796 2.03 syndecan binding protein SDCBP 8q12.1
504916 2.03 hypothetical protein MGC10812 MGC10812 19p13.11
4279563 2.02 tissue factor pathway inhibitor 2 TFPI2 7q21.3
172079 2.01 triosephosphate isomerase 1 TPI1 12p13.31
503300 2.01 hypothetical protein LOC51315 LOC51315 1p36.33
200586 2.00 metallothionein 1B MT1B 16q12.2
23904 2.00 ELOVL family member 5, elongation of long chain fatty acids ELOVL5 6p12.1
N/A Not available.
*SAM analysis with FDR 0.07-0.8%, fold change 2.
yRelative fold change between the two classes (resistant/sensitive).
zList of genes whose transcript levels are greater in the resistant compared to the sensitive group.
§List of genes whose transcript levels are less in the resistant compared to the sensitive group.
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Table W2. Test of Agreement between Expression Changers and Discriminate Genomic Regions.
Expression Microarray BAC CGH*
Cytoband Regions Gained Cytoband Regions with No Change Cytoband Regions Lost
Number of Genes with Greater
Transcript Levelsy
2O** 10 0 12
Number of Genes with No Change 320 6194O 175 6689
Number of Genes with Lower
Transcript Levelsy
7 95 8O** 110
TOTAL 329 6299 183 6811
Cohen’s Kappa = 0.0230z
Test of Ho: Kappa = 0: j ^* = 0.1316
§
*Cytoband regions gained, lost, or with no change in the resistant compared to the sensitive group that were identified by the Fisher Exact test (P < 0.05).
yGenes whose transcript levels were determined to be significantly greater or lower in the resistant compared to the sensitive group by SAM analysis (FDR 0.7-
0.08%, FC 2).
zSlight agreement between the expression and BAC CGH data (0 < j^* < 1).
§Agreement does not exceed chance (j ^* < 1.96).
OOverall agreement between aCGH and expression data was 91%.
**8.2% of SAM changers agree with changes in copy number.
Table W3. Overall Losses and Gains.
Loss Gain
1p36.11-pter; 3p22.1-p21.31;
4p15.33-p16.1; 4p12-p14; 4q13.2-qter;
5q13.1-q23.3; 6q22.1-qter; 8p21.1-pter;
9p; 9q21.11-q33.1; 11p15.1-pter;
13q12.2-q21.1; 13q32.2-qter;
15q11.2-q15.1; 16q; 17p13.2-q11.2;
17q21.32-q21.33; 18q21.1-qter; 22
1q11-q25.3; 2p22.3-pter;
3q22.3-qter; 6p22.1-pter;
6p21.1-p21.31; 7q31.33-qter;
8q; 12p; 20p12.1-pter;
20q12-qter
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